Accès gratuit
| Numéro |
Therapie
Volume 66, Numéro 4, Juillet-Août 2011
|
|
|---|---|---|
| Page(s) | 301 - 307 | |
| Section | Pharmacologie sociétale / Social Pharmacology | |
| DOI | https://doi.org/10.2515/therapie/2011049 | |
| Publié en ligne | 19 août 2011 | |
- Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009 Dec; 8(12) : 959-68 [CrossRef] [PubMed] [Google Scholar]
- Eichler HG, Aronsson B, Abadie E, et al. New drug approval success rate in Europe in 2009. Nat Rev Drug Discov 2010 May 9(5), 355-6 [CrossRef] [PubMed] [Google Scholar]
- Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 Nov 22; 357(21) : 2109-22 [CrossRef] [PubMed] [Google Scholar]
- Learning lessons from Pfizer’s $800 million failure. Nat Rev Drug Discov 2011 Mar; 10(3) : 163-4 [Google Scholar]
- Woodcock J. Precompetitive research : a new prescription for drug development? Clin Pharmacol Ther 2010 May; 87(5) : 521-3 [CrossRef] [PubMed] [Google Scholar]
- Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity : the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010 Mar; 9(3) : 203-14 [PubMed] [Google Scholar]
- Nathan C. Aligning pharmaceutical innovation with medical need. Nat Med 2007 Mar; 13(3) : 304-8 [CrossRef] [PubMed] [Google Scholar]
- Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. PharmacoEconomics 2002; 20(Suppl 3) : 11-29 [CrossRef] [Google Scholar]
- http://www.corem.qc.ca [Google Scholar]
- Carayannis EG, Alexander J. Strategy, structure, and performance issues of precompetitive R&D consortia : insights and lessons learned from SEMATECH. Engineering Management IEEE Transactions on May 2004; 51 (2) : 226-32 [CrossRef] [Google Scholar]
- http://www.tifn.nl [Google Scholar]
- http://www.alzheimer-europe.org/FR/Research/PharmaCog [Google Scholar]
- http://newmeds-europe.com [Google Scholar]
- http://www.sagebase.org [Google Scholar]
- Derry JMJ, Mangravite LM, Suver C, et al. Developing predictive molecular maps of human disease through community-based modeling. Nature Precedings April 2011 http://precedings.nature.com/documents/5883/version/1/files/npre20115883-1.pdf [Google Scholar]
- Julien S, Merino-Trigo A, Lacroix L, et al. CReMEC initiative : characterization of patient-derived colorectal tumor models and correlation with patient profile. Proc Am Assoc Cancer Res, 2010 abst. 4169 http://www.oncodesign.fr/posters/2010/AACR2010CReMEC.pdf [Google Scholar]
- Altshuler JS, Balogh E, Barker AD, et al. Opening up to precompetitive collaboration. Sci Transl Med 2010 Oct 6; 2(52) : 52-26 [Google Scholar]
- Melese T, Lin SM, Chang JL, et al. Open innovation networks between academia and industry : an imperative for breakthrough therapies. Nat Med 2009May; 15(5) : 502-7 [CrossRef] [PubMed] [Google Scholar]
- Friend SH. The need for precompetitive integrative bionetwork disease model building clinical pharmacology & therapeutics. Clin Pharmacol Ther 2010; 87(5) : 536-9 [CrossRef] [PubMed] [Google Scholar]
- http://www.biomerkersconsortium.org [Google Scholar]
- Wagner JA, Prince M, Wright EC, et al. The Biomarkers consortium : practive and pitfalls of ope-source precompetitive collaboration. Clin Pharmacol Ther 2010; 87 : 539-42 [CrossRef] [PubMed] [Google Scholar]